Effect of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by streptococcus pneumoniae - Alaska, 2008-2012

Journal of Infectious Diseases

Volumn 209, Issue 8, 2014, Pages 1251-1258

  Gounder, Prabhu P ^a   Bruce, Michael G ^a   Bruden, Dana J T ^a   Singleton, Rosalyn J ^a,b   Rudolph, Karen ^a   Hurlburt, Debby A ^a   Hennessy, Thomas W ^a   Wenger, Jay ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

Author keywords

Alaska; Alaska Native people; conjugate vaccine; nasopharyngeal colonization; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; BACTERIAL COLONIZATION; CHILD; CONFERENCE PAPER; FEMALE; HUMAN; MALE; NASOPHARYNX; NONHUMAN; PNEUMOCOCCAL INFECTION; PREVALENCE; PRIORITY JOURNAL; RURAL AREA; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; THROAT CULTURE; UNITED STATES; URBAN AREA; VACCINATION;

ALASKA; ALASKA NATIVE PEOPLE; CONJUGATE VACCINE; NASOPHARYNGEAL COLONIZATION; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ALASKA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; NASOPHARYNGEAL DISEASES; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PREVALENCE; RURAL POPULATION; STREPTOCOCCUS PNEUMONIAE; URBAN POPULATION; VACCINATION;

EID: 84897453215     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit642     Document Type: Conference Paper

References (29)

1. Davidson M, Schraer CD, Parkinson AJ, et al. Invasive pneumococcal disease in an Alaska native population, 1980 through 1986. JAMA 1989; 261:715-8.
2. Rudolph KM, Parkinson AJ, Reasonover AL, Bulkow LR, Parks DJ, Butler JC. Serotype distribution and antimicrobial resistance patterns of invasive isolates of Streptococcus pneumoniae: Alaska, 1991-1998. J Infect Dis 2000; 182:490-6.
3. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007; 297:1784-92.
4. Davidson M, Parkinson AJ, Bulkow LR, Fitzgerald MA, Peters HV, Parks DJ. The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990: Ethnic differences and opportunities for prevention. J Infect Dis 1994; 170:368-76.
5. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: The key to pneumococcal disease. Lancet Infect Dis 2004; 4:144-54.
6. Hennessy TW, Singleton RJ, Bulkow LR, et al. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: Progress towards elimination of a health disparity. Vaccine 2005; 23:5464-73.
7. Hammitt LL, Bruden DL, Butler JC, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: An explanation of trends in invasive pneumococcal disease. J Infect Dis 2006; 193:1487-94.
8. Wenger JD, Zulz T, Bruden D, et al. Invasive pneumococcal disease in Alaskan children: Impact of the seven-valent pneumococcal conjugate vaccine and the role of water supply. Pediatr Infect Dis J 2010; 29:251-6.
9. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 2005; 116: E408-13.
10. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-51.
11. Ghaffar F, Barton T, Lozano J, et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 2004; 39:930-8.
12. Byington CL, Samore MH, Stoddard GJ, et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: Emergence of nonvaccine serogroups. Clin Infect Dis 2005; 41:21-9.
13. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007; 196:1346-54.
14. Centers for Disease C, Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59:258-61.
15. Food and Drug Administration (FDA). Prevnar 13: Clinical review of new product license application. Rockville, MD: FDA, 2010.
16. Department of Labor and Workforce Development. Census and geographic information. State of Alaska: Juneau. http://laborstats.alaska.gov/census/. Accessed 3 October 2013.
17. Singleton R, Wenger J, Klejka JA, et al. The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: Results of a clinical trial. Pediatr Infect Dis J 2013; 32:257-63.
18. O'Brien KL, Bronsdon MA, Dagan R, et al. Evaluation of a medium (STGG) for transport and optimal recovery of Streptococcus pneumoniae from nasopharyngeal secretions collected during field studies. J Clin Microbiol 2001; 39:1021-4.
19. Miernyk K, Debyle C, Harker-Jones M, et al. Serotyping of Streptococcus pneumoniae isolates from nasopharyngeal samples: Use of an algorithm combining microbiologic, serologic, and sequential multiplex PCR techniques. J Clin Microbiol 2011; 49:3209-14.
20. Orenstein WA, Bernier RH, Dondero TJ, et al. Field evaluation of vaccine efficacy. BullWorld Health Organ 1985; 63:1055-68.
21. National Center for Immunization and Respiratory Diseases. Centers for Disease Control and Prevention, Department of Health and Human Services: Atlanta. Statistics and surveillance: Vaccination coverage in the U.S. http://wwwdev.cdc.gov/vaccines/stats-surv/imz-coverage.htm#nis. Accessed 28 September 2012.
22. Hussain M, Melegaro A, Pebody RG, et al. A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiol Infect 2005; 133:891-8.
23. Hoshino K, Watanabe H, Sugita R, et al. High rate of transmission of penicillin-resistant Streptococcus pneumoniae between parents and children. J Clin Microbiol 2002; 40:4357-9.
24. Givon-Lavi N, Fraser D, Dagan R. Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings. Pediatr Infect Dis J 2003; 22:524-32.
25. Hennessy TW, Ritter T, Holman RC, et al. The relationship between inhome water service and the risk of respiratory tract, skin, and gastrointestinal tract infections among rural Alaska natives. Am J Public Health 2008; 98:2072-8.
26. Lipsitch M. Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae. Clin Infect Dis 2001; 32:1044-54.
27. Schrag SJ, Pena C, Fernandez J, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: A randomized trial. JAMA 2001; 286:49-56.
28. Muhlemann K, Matter HC, Tauber MG, Bodmer T; Sentinel Working Group. Nationwide surveillance of nasopharyngeal Streptococcus pneumoniae isolates from children with respiratory infection, Switzerland, 1998-1999. J Infect Dis 2003; 187:589-96.
29. Moore MR, Hyde TB, Hennessy TW, et al. Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska. J Infect Dis 2004; 190:2031-8.